Please assess the completion status of the following clinical trial:

Trial Title: US Phase III Study of APD421 in PONV

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients ≥ 18 years of age~* Patients undergoing elective surgery (open or laparoscopic technique) under general anaesthesia, expected to last at least one hour from induction of anaesthesia to wound closure and expected to require at least one overnight stay in hospital~Exclusion Criteria:~* Patients scheduled for outpatient/day case surgery~* Patients scheduled to undergo intra-thoracic, transplant or central nervous system surgery~* Patients scheduled to receive only a local anaesthetic/regional neuraxial (intrathecal or epidural) block~* Patients who are expected to remain ventilated for a period after surgery~* Patients who are expected to need a naso- or orogastric tube in situ after surgery is completed

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- APD421 (Type: EXPERIMENTAL): APD421 (amisulpride), at 5mg given by single intravenous (IV) administration by slow push over one minute at induction of anaesthesia.
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo given by single IV administration by slow push over one minute at induction of anaesthesia

Based on this trial design, predict the completion outcome and termination type (if applicable).